Author

S. Varambally

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Assay:bulk RNA-seq· 4 Research Focus:drug response / drug discovery· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

D. S. Chandrashekar· 4 shared G. Naik· 2 shared G. Sonpavde· 2 shared J. E. Ferguson· 2 shared M.-L. Eich· 2 shared N. Palanisamy· 2 shared S. Agarwal· 2 shared S. Carskadon· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

D. S. Chandrashekar

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Targeted inhibition of BET proteins in HPV-16 associated head and neck squamous cell carcinoma reveals heterogeneous transcription response

A. Rao, Z. Ni, D. Suresh, C. Mohanty, A. Wang, D. Lee, K. Nickel, S. Varambally, R. J. Kimple, P. F. Lambert, C. Kendziorski, G. Iyer

This study shows BET inhibition reduces E6 and E7 expression in HPV-16 HNSCC, with variable effects on p53 and Rb, and induces G1 arrest and apoptosis.

bioRxiv · Oct 2, 2023 · PreprintCancer Biology

TGF-B signaling suppresses TCA cycle metabolism in renal cancer.

H. Nam, A. Kundu, S. Karki, G. Brinkley, D. S. Chandrashekar, R. L. Kirkman, J. Liu, M. V. Liberti, J. W. Locasale, T. Mitchell, S. Varambally, S. Sudarshan

This study shows that TGF-β signaling suppresses TCA cycle enzyme expression in renal cancer, leading to reduced mitochondrial metabolism and tumor growth.

bioRxiv · Feb 19, 2021 · PreprintCancer Biology

ARID1A-mutant and deficient bladder cancer is sensitive to EZH2 pharmacologic inhibition

J. E. Ferguson, H. Rehman, D. S. Chandrashekar, B. Chakravarthi, S. Nepal, M.-L. Eich, A. Robinson, S. Agarwal, S. A. H. Balasubramanya, G. Naik, U. Manne, G. Netto, C.-x. Pan, G. Sonpavde, S. Varambally

This study shows that ARID1A-deficient bladder cancer cells are sensitive to EZH2 inhibition, suggesting a therapeutic strategy for patients with ARID1A mutations.

bioRxiv · Jan 12, 2021 · PreprintCancer Biology

Therapeutically actionable PAK4 is amplified, overexpressed and involved in bladder cancer progression

D. S. Chandrashekar, B. V. S. K. Chakravarthi, A. D. Robinson, J. C. Anderson, S. Agarwal, S. A. Hodigere Balasubramanya, M.-L. Eich, A. K. Bajpai, S. Davuluri, M. S. Guru, A. S. Guru, G. Naik, D. L. Della Manna, K. K. Acharya, S. Carskadon, , S. Varambally

This study identifies PAK4 amplification and overexpression in bladder cancer and shows PAK4 inhibition reduces tumor growth, with potential for combination therapy.

bioRxiv · Aug 20, 2019Cancer Biology

Pseudogene associated recurrent gene fusion in prostate cancer

B. V. Chakravarthi, P. D. Arachchige, S. Carskadon, S. Kalyana-Sundaram, J. Li, K.-H. H. Wu, D. S. Chandrashekar, J. O. Peabody, H. Stricker, C. Hwang, D. A. Chitale, S. R. Williamson, N. S. Gupta, N. M. Navone, C. Rogers, , N. Palanisamy

The paper identifies and validates a novel gene fusion in prostate cancer involving KLK4 and KLKP1, showing its association with high Gleason grade tumors and potential as a biomarker.

bioRxiv · Jun 11, 2019Cancer Biology